A5102964138- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Nonmelanoma Skin Cancer Studies
- Global Cancer Incidence and Screening
- Head and Neck Cancer Studies
- Statistical Methods in Clinical Trials
- Molecular Biology Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Advanced Radiotherapy Techniques
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Family Support in Illness
- Cancer survivorship and care
- Epigenetics and DNA Methylation
- Cervical Cancer and HPV Research
- DNA Repair Mechanisms
- Cancer-related molecular mechanisms research
- Cancer-related Molecular Pathways
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- RNA modifications and cancer
- Economic and Financial Impacts of Cancer
Sylvester Comprehensive Cancer Center
2020-2025
University of Miami
2020-2025
SUNY Upstate Medical University
2023
Massachusetts General Hospital
2019-2023
Hunter College
2023
City University of New York
2023
Memorial Sloan Kettering Cancer Center
2023
University College London
2022
The Royal Free Hospital
2022
Ospedale Santa Chiara
2022
Human papillomavirus (HPV)-positive oropharyngeal head and neck squamous cell carcinoma (OPSCC) is increasing in the United States. Current epidemiologic assessments of national burden HPV-positive OPSCC are needed.The Surveillance Epidemiology End Results HPV Status Database included 12,017 patients with pharyngeal subsites, including non-OPSCC cancer subsites (hypopharynx, nasopharynx, "other pharynx"), diagnosed from 2013 to 2014. Age-adjusted incidence rates per 100,000 persons by status...
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
Abstract Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications AR-A treatment-naïve primary largely unknown. We sought to characterize localized understand its molecular implications. Experimental Design: Genome-wide expression profiles from prostatectomy or biopsy samples 19,470 patients were used, all with independent pathology...
<h3>Importance</h3> In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated overall survival (OS) in the NRG/RTOG 9601 study. However, hormone has morbidity, and there are no validated predictive biomarkers identify which patients derive most benefit from treatment. <h3>Objective</h3> To examine role pre-SRT prostate-specific antigen (PSA) levels personalize use SRT. <h3>Interventions</h3> Men were randomized SRT plus...
Background We sought to determine the extent which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate‐specific antigen screening may have impacted recent prostate cancer disease incidence patterns in United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups. Methods SEER*Stat version 8.3.4 was used calculate annual rates from 2010 2015 for men aged ≥50 years according American Joint Committee on stage at...
Abstract Racial disparities in prostate cancer have not been well characterized on a genomic level. Here we show the results of multi-institutional retrospective analysis 1,152 patients (596 African-American men (AAM) and 556 European-American (EAM)) who underwent radical prostatectomy. Comparative analyses between race groups were conducted at clinical, genomic, pathway, molecular subtype, prognostic levels. The EAM group had increased ERG ( P < 0.001) ETS = 0.02) expression, decreased...
Active surveillance (AS) is recommended for low-risk and some intermediate-risk prostate cancer. Uptake practice of AS vary significantly across different settings, as does the experience surveillance-from which tests are offered, to levels psychological support.To explore current best determine most important research priorities in cancer.A formal consensus process was followed, with an international expert panel purposively sampled participants a range health care professionals...
Background There are a growing number of cancer survivors in the United States who at risk for chronic pain due to disease and treatments. The prevalence among has not been comprehensively reported. Methods This study used data from National Health Interview Survey (2010‐2017) compare between participants with diagnosis without one. Adjusted odds ratios (AORs) having were assessed by multivariable logistic regression, which included an age (less than median vs greater or equal age) × (yes...
Background: Alcohol use is an established risk factor for several malignancies and associated with adverse oncologic outcomes among individuals diagnosed cancer. The prevalence patterns of alcohol cancer survivors are poorly described. Methods: We used the National Health Interview Survey from 2000 to 2017 examine drinking adults reporting a diagnosis. Multivariable logistic regression was define association between demographic socioeconomic variables odds self-reporting as current drinker,...
Background Socioeconomic factors affecting outcomes of HPV-associated squamous cell carcinoma the head and neck (SCCHN) are poorly characterized. Methods A custom SEER database identified adult patients with primary nonmetastatic SCCHN known HPV status diagnosed in 2013 through 2014. Multivariable logistic regression defined associations between patient characteristics status, adjusted odds ratios (aORs) 95% confidence intervals reported. Fine-Gray competing risks estimated hazard (aHRs) for...
239 Background: Despite several improvements in Active Surveillance (AS), pathologic reclassification remains frequent. Therefore, we examined if gene expression signatures biopsy cores with Gleason Group (GG) 1 cancer can predict coexisting higher-grade disease elsewhere the prostate among participants of Miami Trial (MAST). Methods: MAST enrolled 205 men low and favorable intermediate-risk undergoing AS. Participants underwent an MRI confirmatory at enrollment, annually thereafter for...
240 Background: Prostate cancer is heterogeneous and multi-focal, biopsy sampling often undersamples the tumor or samples different foci. Such heterogeneity can lead to inaccurate molecular classifications of biology on tissue-based prognostic tests. Consequently, this impacts treatment decision making management in localized prostate cancer. Herein, we evaluate degree variability transcriptomic profiles when assessing genomic from MRI-guided versus template using Decipher GRID platform....
262 Background: The progression of prostate cancer through serial biopsies in patients on active surveillance is a multifaceted process, with grade and volume offering unique perspectives disease advancement. Decipher genomic classifier has been recognized as valuable tool for predicting progression. This study examines the relationship between score, other GRID signatures pathways, patients, utilizing data collected prospectively from Miami Active Surveillance Trial (MAST). Methods: We...
24 Background: The number of prostate cancer cases globally is projected to double from 2020 2040. However, significant global variation exists in incidence and mortality. A more specific understanding health system levers may inform planning. Therefore, we used data the World Health Organization (WHO), Bank, Directory Radiotherapy Centres (DIRAC), United Nations Development Programme (UNDP), International Agency for Research on Cancer (IARC) evaluate predictors outcomes globally. Methods:...